Voyager Therapeutics, Inc..
VYGR.US | Research and experimental development on natural sciences and engineering
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases. The company engineers and optimizes adeno-associated virus (AAV) vectors to precisely deliver genes to target areas of the brain. Voyager's pipeline i...Show More
Better Health for All
60
Voyager Therapeutics is a clinical-stage gene therapy company entirely focused on developing treatments for serious neurological diseases such, as Parkinson's, Alzheimer's, Friedreich's ataxia, and Gaucher disease.
1
Its pipeline aims to deliver revolutionary health benefits by addressing the underlying causes of these conditions, with no products identified as having negative health outcomes. The company reported R&D expenses of $30.2 million in Q3 2024
2
and $31.5 million in Q1 2025,
3
representing 100% of its operational focus on health innovation. In terms of safety, its anti-tau antibody VY7523 demonstrated safety and tolerability in a single ascending dose trial involving 48 healthy volunteers, with no serious adverse events or infusion reactions reported.
4
The company conducts randomized, double-blind, placebo-controlled clinical trials for its investigational drugs.
5
Fair Money & Economic Opportunity
0
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, and its core business does not involve offering lending, deposit, or other financial services to consumers.
1
As such, the company does not offer consumer credit products, manage customer finance data, or operate financial service access points.
2
Therefore, all KPIs under the 'Fair Money & Economic Opportunity' value are deemed not applicable, as the company's operations do not align with the scope of this value.
Fair Pay & Worker Respect
0
No specific, concrete data points were found across the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. Information regarding living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, and health insurance coverage was explicitly stated as not covered or unavailable in multiple articles.
1
Employee review ratings from third-party sites like Indeed.com (e.g., 4.0 overall, 4.7 for culture) are not considered formal employee engagement survey indices as defined by the rubric.
2
Fair Trade & Ethical Sourcing
0
No data was available from the provided articles to assess Voyager Therapeutics, Inc. against the Fair Trade & Ethical Sourcing value.
1
All articles indicated service outages or unavailable pages, preventing any extraction of specific facts regarding fair trade certifications, audit frequencies, labour incidents, traceability, remediation, ethical clauses, materials risk, or supplier diversity spend.
2
Honest & Fair Business
-40
Voyager Therapeutics maintains a confidential and anonymous financial concern hotline for complaints related to accounting, internal accounting controls, or auditing matters, which is managed by the Audit Committee.
1
However, there is no evidence of independent investigation processes for these reports. The company states compliance with the U.S. Foreign Corrupt Practices Act (FCPA) and other anti-corruption laws, and its collaboration agreements with Pfizer and Novartis include clauses allowing termination for non-compliance with anti-bribery or anti-corruption covenants.
2
The company's consolidated financial statements are certified by Ernst & Young LLP, an independent registered public accounting firm.
3
Additionally, legal opinions from external law firms are provided to underwriters, and Neurocrine has the right to engage an independent third party to audit Voyager’s books and records if a suspected violation of anti-corruption covenants needs investigation.
4
Kind to Animals
0
No evidence available to assess Voyager Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Voyager Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
-20
Voyager Therapeutics has no Science Based Targets Initiative (SBTi) commitment.
1
The company sources 22% of its operational energy consumption from renewables.
2
Its waste diversion rate from landfill by reuse, recycling, or recovery is 62.4%.
3
The company's annual water consumption is 127,500 gallons, which translates to approximately 6.03 m³ per $1 million of revenue based on its 2024 revenue of $80.0 million.
4
Respect for Cultures & Communities
0
No quantitative data related to community relations or cultural sensitivity metrics were found in the provided articles.
1
The company's articles focus on internal company culture, employee resource groups, and general diversity initiatives.
2
No regulatory actions, violations, fines, or compliance issues related to cultural appropriation were mentioned in the provided articles.
3
Safe & Smart Tech
0
No evidence available to assess Voyager Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-30
The company maintains a waste management program that separates compostables and recyclables from other trash to reduce overall waste.
1
For hazardous waste, which includes chemicals, biologic, and radioactive materials, the company generally contracts with third parties for disposal.
2